S-1/A: Profusa Secures $100M Equity Facility Amidst Financial Woes

Profusa, Inc. completed its business combination and secured a $100 million committed equity facility, but faces significant financial challenges including a Nasdaq delisting and a going concern warning.

Summary

• Profusa, Inc. (formerly NorthView Acquisition Corporation) completed its business combination with Profusa, Inc. (California corporation) on July 11, 2025.
• The company entered into a Common Stock Purchase Agreement with Ascent Partners Fund LLC on July 28, 2025, allowing Profusa to sell up to $100,000,000 of its common stock to Ascent over 36 months.
• Ascent Partners Fund LLC is registering for resale up to 8,970,830 shares of common stock, including 8,070,830 Purchase Shares and 900,000 Commitment Warrant Shares.
• Profusa will not receive proceeds from Ascent's resale of shares, but may receive up to $100,000,000 from direct sales to Ascent under the Purchase Agreement.
• Proceeds from sales to Ascent will primarily be used to purchase Bitcoin, provided the cash balance exceeds $5,000,000; otherwise, it will first bring the cash balance to $5,000,000.
• Profusa is a clinical-stage digital health and medical technology company developing biointegrated sensors, including the Lumee Oxygen Platform (CE Mark approved, targeting EU commercialization in early 2026, US FDA submission late 2026) and Lumee Glucose Platform (in clinical trials, targeting EU launch in 2025, US approval late 2026/early 2027).
• The company reported a net loss of $5.1 million for the six months ended June 30, 2025, and $9.2 million for the year ended December 31, 2024.
• Profusa has a working capital deficit of approximately $63.2 million as of June 30, 2025, and management has substantial doubt about its ability to continue as a going concern.
• The company has a significant patent portfolio with 20 issued U.S. patents and 80 rest-of-world patents, expiring between March 2030 and January 2040.

Sentiment

Score: 3

Explanation: Despite securing a committed equity facility and having promising product development, the company faces severe financial challenges, including substantial doubt about its going concern status, significant losses, a large working capital deficit, and a Nasdaq delisting. The high-risk Bitcoin treasury strategy adds further uncertainty.

Positives

• Secured a Committed Equity Facility with Ascent Partners Fund LLC for up to $100,000,000, providing a potential source of capital.
• Successful completion of the business combination on July 11, 2025, transitioning Profusa into a public company.
• Lumee Oxygen Platform has received CE Mark approval in the EU, with commercialization anticipated in early 2026.
• Lumee Glucose Platform has shown promising proof-of-concept clinical data with a Mean Absolute Relative Difference (MARD) of approximately 11% and up to nine months of functionality post-injection, with zero device-related serious adverse events (SAE) in trials involving 54 subjects.
• Extensive intellectual property portfolio with 20 issued U.S. patents and 80 rest-of-world patents, protecting its core technology.
• Strategic plan to leverage partnerships for commercialization in Europe and Asia Pacific, and for data streams in telemedicine and health & wellness sectors.
• Management believes its technology offers advantages over current glucose monitoring solutions, potentially expanding the user base to Type 2 and pre-diabetes populations.

Negatives

• Profusa has incurred significant net operating losses since inception, with a net loss of $5.1 million for the six months ended June 30, 2025, and $9.2 million for the year ended December 31, 2024.
• Substantial doubt about the company's ability to continue as a going concern, despite recent financing, due to recurring losses and significant cash burn.
• Working capital deficit of approximately $63.2 million as of June 30, 2025.
• Reliance on the highly volatile Bitcoin market for the use of proceeds from the equity facility, which could negatively impact financial results.
• Lumee Glucose is an investigative product and not yet authorized for commercial sale in any jurisdiction, and Lumee Oxygen is not yet approved for commercial sale in the U.S.
• The company is in default on its PPP Loan 2 ($1.383 million outstanding as of June 30, 2025) and certain promissory notes ($0.940 million outstanding as of June 30, 2025).
• The company's common stock was delisted from Nasdaq on December 27, 2024, and now trades on the OTC Market, which can negatively affect liquidity and market price.
• The $100,000,000 committed equity facility is at Profusa's discretion to draw upon, and actual sales will depend on market conditions and the trading price of common stock.
• The issuance of shares under the committed equity facility will cause dilution to existing stockholders.
• The company has identified material weaknesses in its internal control over financial reporting as of June 30, 2025, related to segregation of duties and review of financial accounts.

Risks

• It is not possible to predict the actual number of shares of Common Stock, if any, that will be sold under the Purchase Agreement to Ascent, or the actual gross proceeds resulting from those sales.
• The sale and issuance of Common Stock to the Selling Stockholder will cause dilution to existing stockholders, and the sale of ELOC Shares acquired by the Selling Stockholder, or the perception that such sales may occur, could cause the price of Common Stock to fall.
• Investors who buy ELOC Shares from the Selling Stockholder at different times will likely pay different prices.
• The net proceeds from sales of Common Stock made pursuant to the Purchase Agreement, if any, will be used primarily to purchase Bitcoin, the price of which has been, and will likely continue to be, highly volatile.
• Substantial doubt exists about the company's ability to continue as a going concern, which may hinder its ability to obtain further financing.
• The company has a limited operating history and has incurred losses since inception, anticipating continued significant losses for at least the next several years.
• The company operates in a highly competitive market and faces competition from large, well-established companies with significant resources.
• International operations expose the company to risks such as local product preferences, longer payment cycles, foreign currency fluctuations, less intellectual property protection, trade protection measures, and political/economic instability.
• Consumer confusion about product features and technology could lead to purchasing competitive products or conflating adverse events with the company's products.
• Commercialization of the Lumee Oxygen Platform is expected to generate nearly all commercial revenue until regulatory approval for additional products is obtained.
• Dependence on third-party suppliers and outsourcing makes the company vulnerable to supply disruptions, suboptimal quality, noncompliance, and price fluctuations.
• There is no guarantee that the FDA will grant 510(k) clearance or PMA approval of products, and failure to obtain necessary clearances or approvals would adversely affect business growth.
• Inability to successfully complete pre-clinical studies or clinical trials necessary to support additional PMA, De Novo, or 510(k) applications or supplements.
• Products may cause or contribute to adverse medical events or be subject to failures or malfunctions that require reporting to the FDA, potentially leading to sanctions or recalls.
• Quality problems could lead to recalls or safety alerts, reputational harm, and material adverse effects on business.
• Current or future products may be subject to product recalls even after receiving FDA clearance or approval.
• Changes to the regulatory landscape may impact the ability to obtain marketing authorization for future product developments.
• Failure to comply with laws, regulations, and contract requirements relating to reimbursement of health care goods and services may subject the company to penalties.
• Subject to complex and evolving U.S. and foreign laws and regulations regarding privacy, data protection, and security, which could result in claims, penalties, and increased costs.
• Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems.
• May become subject to claims of infringement or misappropriation of the intellectual property rights of others.
• Involvement in lawsuits to protect or enforce patents could be expensive, time-consuming, and unsuccessful.
• Inability to protect intellectual property rights throughout the world.
• Failure to protect the confidentiality of trade secrets could materially adversely affect the value of technology.
• May need or choose to obtain licenses from third parties to advance research or commercialization, and there is no assurance such licenses would be obtainable.
• Obtaining and maintaining patent protection depends on compliance with various procedural requirements, and protection could be reduced or eliminated for non-compliance.
• If patent term extension and/or data exclusivity are not obtained for any product candidates developed as drug product candidates, business may be materially harmed.
• Inability to successfully maintain effective internal control over financial reporting could adversely impact investor confidence and stock price.
• Environmental, social, and corporate governance (ESG) regulations, policies, and provisions may make the supply chain more complex and adversely affect customer relationships.
• Uncertainty in domestic and global economic and political conditions makes it difficult to predict product demand.
• Changes in financial accounting standards or practices or existing taxation rules or practices may cause adverse unexpected revenue and/or expense fluctuations.
• Material weaknesses identified in internal control over financial reporting could continue to adversely affect the ability to report financial results accurately and timely.
• Failure to maintain an effective system of disclosure controls and internal control over financial reporting could impair the ability to produce timely and accurate financial statements.
• Bitcoin treasury strategy exposes the company to various risks associated with Bitcoin, including high volatility, lack of interest/dividends, untested strategy, and counterparty risks.
• Regulatory change reclassifying Bitcoin as a security could lead to classification as an investment company under the Investment Company Act of 1940.
• Bitcoin holdings are less liquid than cash and cash equivalents and may not serve as a source of liquidity to the same extent.
• Security breaches or cyberattacks resulting in unauthorized access to Bitcoin, or loss/destruction of private keys, could lead to loss of Bitcoin.
• The broader digital assets industry is subject to counterparty risks, which could adversely impact the adoption rate, price, and use of Bitcoin.
• Changes in the accounting treatment of Bitcoin holdings could have significant accounting impacts, including increasing the volatility of financial results.
• The concentration of Bitcoin holdings will enhance the risks inherent in the Bitcoin treasury strategy.
• The emergence or growth of other digital assets could have a negative impact on the price of Bitcoin.
• A temporary or permanent blockchain fork to Bitcoin or other crypto assets could adversely affect the business.
• Due diligence procedures conducted to mitigate transaction risk may fail to prevent transactions with a sanctioned entity.
• No assurance that the company will be able to comply with Nasdaq continued listing standards, a failure of which could result in a de-listing of common stock.
• Future sales, or the perception of future sales, by shareholders in the public market could cause the market price for common stock to decline.
• The grant and future exercise of registration rights may adversely affect the market price of shares.
• Shares of common stock reserved for future issuance under the Equity Incentive Plan will become eligible for sale in the public market once those shares are issued.
• No current plans to pay cash dividends on common stock for the foreseeable future.
• Issuance of additional shares of common stock or other equity securities without stockholder approval would dilute ownership interests and may depress the market price.
• Anti-takeover provisions in the amended and restated certificate of incorporation and under Delaware law could make an acquisition more difficult.
• Exclusive forum provisions could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Securities litigation is expensive and could divert management attention.

Future Outlook

Profusa expects to continue substantial investments in building its European and United States commercial infrastructure, enhancing existing products, and developing new ones. The company aims to continue discussions with potential partners in Asia. It anticipates incurring additional expenses as a public company due to regulatory compliance, insurance, and investor relations. Additional financing will be required to fund operations and planned growth, potentially through equity offerings, debt financings, or credit facilities. The Lumee Oxygen Platform is expected to commercialize in Europe in early 2026 and seek U.S. FDA marketing authorization late 2026. The Lumee Glucose Platform is expected to launch in Europe in 2025 and seek U.S. approval in late 2026 or early 2027. The company plans to use proceeds from the Committed Equity Facility primarily for Bitcoin purchases, provided cash balances exceed $5 million.

Management Comments

• Management believes this liquidity has not alleviated the relevant conditions or events that raise substantial doubt about the Company's ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued.
• Management is targeting the European market (those jurisdictions that accept CE mark) for early launch for both Lumee Oxygen and Lumee Glucose.
• We feel a difference between other insertable or implantable CGMs and Lumee Glucose, is that the latter can be simply inserted with a hypodermic needle and does not require a surgical implantation, similar to how pharmacists use these needles to administer flu shots and other vaccines.
• Profusa believes that the combination of the potential advantages of this platform will enable it to generate both short-term revenue in the high-value clinical applications of wound care and diabetes management as noted above, but to also leverage core technology and develop and add to Profusa's product portfolio to potentially tackle the management of other chronic conditions, while in the future creating the foundation for the technology enabled health care where the large volume of biomarker data aligned with up-to-the-minute actions and choices of the individual.
• Profusa believes that Lumees biosensor and artificial intelligence platform compares very attractively with some of the largest products in this market sector.
• Profusa believes its validated core technology can easily bridge the gap that exists in the current technology landscape for monitoring real time biochemistry.
• Profusa believes that, at scale, the data Profusa's platform generates from its initial products will be a key enabler for the productivity and business models for both of these sectors to expand and reach more of their full potential.

Industry Context

The company operates in the highly competitive digital health and medical technology industry, specifically in biointegrated sensors for oxygen and glucose monitoring. The market for continuous glucose monitoring (CGM) is estimated at $2.8 billion in the U.S. and over $800 million in Europe by end of 2024, while the oxygen monitoring market is over $2 billion in the U.S. and over $700 million in Europe. Profusa faces competition from large, well-established companies like Abbott Laboratories, Medtronic plc, Roche Diabetes Care, LifeScan, Inc., and Ascensia Diabetes Care in CGM, and Siemens Healthineers, Perimed AB, SenTec AG, Radiometer Medical, MESI, and ATYS Medical in oxygen monitoring. The industry is characterized by rapid technological change and evolving standards. There's a growing trend towards technology-enabled healthcare, telemedicine, and remote patient monitoring, with CMS implementing reimbursement codes for RPM. Profusa aims to capitalize on the need for real-time, clinically reliable data in these high-growth sectors. The company's strategy of developing long-term, easily deployable, and cost-effective sensors positions it against current CGM solutions that are often inconvenient, require frequent changes, or surgical implantation. The company also notes the increasing focus on ESG regulations in supply chains within the medical device industry.

Comparison to Industry Standards

• Lumee Glucose is designed to provide continuous glucose monitoring with a single injection for several months, offering an attractive alternative to frequent finger sticks or weekly sensor replacements required by current short-term needle-type CGMs (e.g., Dexcom G6, Abbott Freestyle Libre 2, Medtronic Guardian Connect, Senseonics Eversense E3 which typically last 7-14 days or 12 months with surgical implantation).
• Lumee Glucose has demonstrated a potential Mean Absolute Relative Difference (MARD) of approximately 11% with up to nine months of functionality post-injection in clinical studies, which is a key metric for CGM accuracy. (For context, many commercial CGMs aim for MARD values below 10%, with some achieving 8-9%, so 11% is competitive but not leading).
• The Lumee Oxygen Platform is designed to report reliable tissue oxygen levels for both acute and long-term monitoring, competing with devices like transcutaneous oximetry (TCPO2) devices from Perimed AB, Radiometer Medical, or SenTec AG, and doppler/cuff devices measuring ABI/TBI/SPP.
• Profusa's sensor deployment via a hypodermic needle is less invasive than surgically implanted solutions, potentially increasing adoption.
• The company's technology aims for lower cost and broader user accessibility compared to existing high-cost CGM solutions, which often limit insurance reimbursement to only the most severe Type 1 and 2 diabetes patients.

Management Changes

Corporate Governance

Legal Proceedings

• Currently defending one litigation with a vendor, with estimated incremental legal costs of less than $0.1 million.

Related Party Transactions

• APAC Joint Venture Term Sheet: Profusa entered into a binding term sheet in July 2020 (amended May 10, 2023) with Carbis Bay Limited, BC hSensor Limited, and Tasly (International) Healthcare Capital Company Limited (Investors) to form a joint venture for commercializing Lumee Glucose and Lumee Oxygen in the Asia Pacific region. Tasly Holding Group Co. Ltd. or its affiliates (Tasly) would purchase 60% of the JV for $6 million, with Profusa retaining 40% and receiving 5% royalties on sales.
• Tasly Convertible Debt: In June 2023, Profusa entered into a short-term loan agreement with Tasly (International) Healthcare Investment & Development Company Limited (a shareholder of Profusa) for up to $1.6 million. The loan bears 12% interest (24% default rate) and matured on December 31, 2023 (extended to March 31, 2024). Profusa is currently in default. The lender has an option to convert outstanding balance and accrued interest into senior unsecured promissory notes or common stock at $1.92 per share.
• Promissory Notes: In 2010 and 2011, two founders provided $0.2 million to Profusa. In 2022, Profusa borrowed $0.3 million from two founders (zero interest, $0.2 million repaid). In 2023, Profusa borrowed $0.3 million from an existing investor and $0.1 million from an unrelated party (12% interest, repayable on demand after December 31, 2024). Profusa is in default on these notes as of December 31, 2023.
• NorthView Convertible Working Capital Promissory Note: NorthView (now Profusa, Inc.) had a convertible working capital promissory note with its Sponsor for up to $2.5 million (non-interest bearing, convertible into warrants at $1.00/warrant or common stock at $2.22/share). The outstanding principal of $1,919,796 was converted into 863,908 shares of New Profusa at $2.22 per share upon the merger closing.
• Administrative Services Agreement: NorthView paid its Sponsor $5,000 per month for office space, utilities, secretarial support, and other administrative and consulting services until June 30, 2023. $50,000 was owed as of June 30, 2025.
• Advances from Profusa: Profusa advanced funds to NorthView for operating expenses, totaling $1,299,040 owed as of June 30, 2025.
• Equity Grants to Executive Officers and Directors: Profusa granted stock options to executive officers and certain directors. Two Key Opinion Leaders (KOLs) received stock options for 10,000 and 30,000 shares, respectively.
• PIPE Transaction: Ascent Partners Fund LLC (Selling Stockholder) is also the PIPE Investor, purchasing senior secured convertible notes.
• Senior Secured Convertible Notes: $10.0 million outstanding with related parties as of June 30, 2025.

Stakeholder Impact

• Shareholders: Will experience significant dilution from the issuance of shares under the committed equity facility and potential future capital raises. The delisting from Nasdaq to the OTC market will reduce liquidity and potentially depress share price. The 'going concern' warning indicates substantial risk to investment.
• Employees: The company's ability to attract and retain skilled personnel is crucial for its growth and product development, especially given the intense competition in the medical device industry. Financial instability could impact employee morale and retention.
• Customers: Potential for new and improved biointegrated sensor products (Lumee Oxygen, Lumee Glucose) could offer better health monitoring solutions. However, delays in regulatory approvals and commercialization could impact product availability.
• Suppliers: Dependence on third-party suppliers makes the company vulnerable to supply disruptions and quality issues, which could affect product manufacturing and delivery.
• Creditors: The company is in default on certain loans and has a significant working capital deficit, posing risks to creditors regarding timely repayment of debt.

Next Steps

• Commercialize Lumee Oxygen Platform in Europe starting early 2026.
• Continue U.S. study for Lumee Oxygen Platform for FDA marketing authorization submission late 2026.
• Launch Lumee Glucose in Europe in 2025, subject to regulatory approval.
• Start next Lumee Glucose validation study in the first half of 2026.
• Seek U.S. FDA approval for Lumee Glucose in late 2026 or early 2027.
• Continue discussions with potential partners in Asia for the APAC Joint Venture.
• Develop products for other analytes (lactate, CO2, ethanol, pH).
• Strategically engage in commercial B2B relationships for data partnerships in telemedicine and health & wellness sectors.
• Remediate identified material weaknesses in internal control over financial reporting.
• File a registration statement for the resale of certain New Profusa Common Stock issuable to PIPE Investors upon conversion of the PIPE Convertible Notes by September 14, 2025.
• Finalize accounting conclusions on Ascent warrants and validate their debt classification for the upcoming September 30, 2025 financial statements.

Key Dates

Recommendation

The company faces severe financial instability, evidenced by recurring significant losses, a substantial working capital deficit, and a 'going concern' warning from management and auditors. The delisting from Nasdaq to the OTC market is a major negative indicator of market confidence and liquidity. While a $100 million committed equity facility is available, its utilization is at the company's discretion and dependent on market conditions, and it will cause significant dilution. The stated strategy of using proceeds to purchase highly volatile Bitcoin introduces an additional layer of extreme risk for a medical device company. These factors collectively point to a highly speculative and risky investment with significant downside potential.

Keywords

Biointegrated Sensors, Continuous Glucose Monitoring, CGM, Lumee Oxygen Platform, Lumee Glucose Platform, Medical Devices, Digital Health, SEC Filing, S-1, Equity Facility, Bitcoin Treasury, Profusa, NorthView Acquisition Corporation, Peripheral Artery Disease, Critical Limb Ischemia, Wound Care, Diabetes Management, Biomarkers, Telemedicine, Health and Wellness, Patent Protection, Regulatory Approval, FDA, CE Mark, Nasdaq Delisting, Dilution, Going Concern, Ascent Partners Fund LLC